Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic p
about
Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic p
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Repeated administration of dap ...... n whole blood transcriptomic p
@en
type
label
Repeated administration of dap ...... n whole blood transcriptomic p
@en
prefLabel
Repeated administration of dap ...... n whole blood transcriptomic p
@en
P2093
P1476
Repeated administration of dap ...... n whole blood transcriptomic p
@en
P2093
Ann M Ranger
Chris Chamberlain
Christian Otoul
Christian Stach
Falk Hiepe
Geoffrey I Johnston
Linda C Burkly
Miren Zamacona
Murray Urowitz
Peter J Colman
P356
10.1136/ANNRHEUMDIS-2017-211388
P407
P50
P577
2017-08-05T00:00:00Z